Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | STAT1 | P42224 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24423742 | 0.80 | HTT (0.34) | HSD17B10KDM4EALDH1A1HPGDALOX15 | |
| SCHEMBL11647885 | 0.69 | HSD17B10 (0.48) | HSD17B10KDM4EALDH1A1HPGDALOX15 | |
| SCHEMBL25539514 | 0.68 | — | — | |
| SCHEMBL15162590 | 0.67 | MAPT (0.38) | HSD17B10KDM4EALDH1A1HPGDALOX15 | |
| SCHEMBL10278091 | 0.67 | HSD17B10 (0.42) | HSD17B10KDM4EALDH1A1HPGDALOX15 | |
| SCHEMBL24837578 | 0.67 | HSD17B10 (0.31) | HSD17B10 | |
| SCHEMBL23607027 | 0.66 | PDE3B (0.33) | — | |
| SCHEMBL24838142 | 0.65 | — | — | |
| SCHEMBL25132240 | 0.65 | — | — | |
| SCHEMBL11648099 | 0.64 | HSD17B10 (0.40) | HSD17B10KDM4EALDH1A1HPGDALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023239645-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| US-10239830-B2 | Benzenesulfonamide upregulators of NPC1 for Neimann-Pick disease and other lysosomal storage disorders | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2019-03-26 | — | — | US | disclosed |
| US-RE46974-E1 | Organic electroluminescence device | IDEMITSU KOSAN CO., LTD. (JP) | 2018-07-31 | — | — | US | disclosed |
| US-20180044286-A1 | BENZENESULFONAMIDE UPREGULATORS OF NPC1 FOR NEIMANN-PICK DISEASE AND OTHER LYSOSOMAL STORAGE DISORDERS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2018-02-15 | — | — | US | disclosed |
| US-20180044286-A1 | BENZENESULFONAMIDE UPREGULATORS OF NPC1 FOR NEIMANN-PICK DISEASE AND OTHER LYSOSOMAL STORAGE DISORDERS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2018-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10239830-B2 | Benzenesulfonamide upregulators of NPC1 for Neimann-Pick disease and other lysosomal storage disorders | GBA1, NPC1, NPC1L1 | HSD17B10 1965/4885KDM4E 2333/4885ALDH1A1 2497/4885 |
| US-20180044286-A1 | BENZENESULFONAMIDE UPREGULATORS OF NPC1 FOR NEIMANN-PICK DISEASE AND OTHER LYSOSOMAL STORAGE DISORDERS | GBA1, NPC1, NPC1L1 | HSD17B10 1965/4885KDM4E 2333/4885ALDH1A1 2497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.